Blood pressure and lipid lowering in the prevention of stroke: A note to neurologists

被引:74
作者
Amarenco, P [1 ]
机构
[1] Univ Paris, Hop Bichat, Dept Neurol, F-75018 Paris, France
关键词
stroke; hypertension; hypercholesterolaemia; statin therapy; angiotensin-converting enzyme inhibitors;
D O I
10.1159/000070275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke is the leading cause of adult disability and dependency in western society. Despite the determined efforts of basic science and clinical investigators, neuroprotective therapies for acute stroke have yet to be realised. Stroke prevention, therefore, remains the key route for reducing morbidity and mortality. Hypertension and hypercholesterolaemia are the most important modifiable risk factors for stroke. Several recent landmark studies have shown that lipid lowering with statins can reduce the risk of ischaemic stroke, as well as coronary heart disease. In addition, clinical trials evaluating the effects of blood pressure lowering have shown that antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs) and angiotensin 11 receptor antagonists can reduce stroke risk. Accumulating evidence suggests certain antihypertensive agents such as CCBs might also prevent the formation and progression of carotid atheroma, independently of their blood-pressure-lowering effects. It follows that rigorous identification and targeting of high-risk or stroke-prone individuals for blood pressure and lipid-lowering interventions should be of practical importance to all physicians involved in the management of stroke. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 37 条
[1]   Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, CW ;
Amarenco, P ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 2001, 119 (01) :300S-320S
[2]   Secondary prevention of stroke and the expanding role of the neurologist [J].
Alberts, MJ .
CEREBROVASCULAR DISEASES, 2002, 13 :12-16
[3]  
*AM HEART ASS, 2001, HEART STROK STAT UPD
[4]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[5]   Stroke, statins, and cholesterol - A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors [J].
Blauw, GJ ;
Lagaay, AM ;
Smelt, AHM ;
Westendorp, RGJ .
STROKE, 1997, 28 (05) :946-950
[6]  
BOSCH J, 2002, BRIT MED J, V324, P1
[7]   Common carotid intima-media thickness and risk of stroke and myocardial infarction - The Rotterdam Study [J].
Bots, ML ;
Hoes, AW ;
Koudstaal, PJ ;
Hofman, A ;
Grobbee, DE .
CIRCULATION, 1997, 96 (05) :1432-1437
[8]   MEDICAL PROGRESS - PRIMARY PREVENTION OF STROKE [J].
BRONNER, LL ;
KANTER, DS ;
MANSON, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (21) :1392-1400
[9]   BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].
COLLINS, R ;
MACMAHON, S .
BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298
[10]   IMPLICATIONS OF SMALL REDUCTIONS IN DIASTOLIC BLOOD-PRESSURE FOR PRIMARY PREVENTION [J].
COOK, NR ;
COHEN, J ;
HEBERT, PR ;
TAYLOR, JO ;
HENNEKENS, CH .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (07) :701-709